60-day Federal Register Notice

Federal Register / Vol. 87, No. 141 / Monday, July 25, 2022 / Notices
or not a complete stock of repair parts
for the items being offered is carried at
that point, and whether or not
mechanical service is available.
Respondents: 3,051.
Responses per respondent: 1.
Total annual responses: 3,051.
Preparation hours per response: .50
(30 minutes).
Total response burden hours: 1,526.
GSAR clause 552.238–99, Delivery
Prices Overseas. This clause requests an
offeror to identify the intended
geographic area(s)/countries/zones
which are covered by their offer.
Respondents: 3,051.
Responses per respondent: 1.
Total annual responses: 3,051.
Preparation hours per response: .50
(30 minutes).
Total response burden hours: 1,526.
GSAR clause 552.238–111,
Environmental Protection Agency
Registration Requirement.** This clause
requests offerors, if applicable, to
identify the manufacturer’s and/or
distributor’s name and EPA Registration
Number for each item offered that
requires registration with the EPA.
Respondents: 3,051.
Responses per respondent: 1.
Total annual responses: 3,051.
Preparation hours per response: 1.0 (1
hr.).
Total response burden hours: 3,051.
** This clause applies to specific GSA
FSS Solicitation Large Categories.
C. Public Comments

lotter on DSK11XQN23PROD with NOTICES1

A 60-day notice published in the
Federal Register at 87 FR 28829 on May
11, 2022. No comments were received.
Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the General Services Administration,
Regulatory Secretariat Division, by
calling 202–501–4755 or emailing
GSARegSec@gsa.gov. Please cite OMB
Control No. 3090–0303, Federal Supply
Schedule Solicitation Information, in all
correspondence.
Jeffrey A. Koses,
Senior Procurement Executive, Office of
Acquisition Policy, Office of Governmentwide Policy.
[FR Doc. 2022–15829 Filed 7–22–22; 8:45 am]
BILLING CODE 6820–61–P

VerDate Sep<11>2014

17:06 Jul 22, 2022

Jkt 256001

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–22–1282; Docket No. CDC–2022–
0092]

Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:

The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled Improving Performance
Measurement and Monitoring by CDC
Programs: The Performance Measures
Project. CDC is requesting approval for
a revision to the previously approved
project to work with selected CDC
programs to provide tools, templates
and technical assistance to develop and
implement performance measures for
CDC funded public health initiatives.
DATES: CDC must receive written
comments on or before September 23,
2022.
SUMMARY:

You may submit comments,
identified by Docket No. CDC–2022–
0092 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road, NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
ADDRESSES:

PO 00000

Frm 00041

Fmt 4703

Sfmt 4703

44121

Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Improving Performance Measurement
and Monitoring by CDC Programs: The
Performance Measures Project (OMB
Control No. 0920–1282, Exp. 01/31/
2023)—Revision—Office of the
Associate Director for Policy and
Strategy (OADPS), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
Each year, approximately 75% of the
CDC’s congressionally appropriated
funding goes to extramural
organizations, including state and local
partners, via contracts, grants, and, most
commonly, cooperative agreements. The

E:\FR\FM\25JYN1.SGM

25JYN1

44122

Federal Register / Vol. 87, No. 141 / Monday, July 25, 2022 / Notices

availability of funding for grants and
cooperative agreements is announced
through a Notice of Funding
Opportunity (NOFO). CDC awards up to
100 new, non-research NOFOs each year
(each funded for one to five years).
These awards may have only a few
funded recipients or more than 50 (such
as when a CDC program provides
funding to all states and territories).
CDC programs develop logic models
for each NOFO, describing the key
programmatic strategies and activities
and the short/medium/long-term
outcomes funded recipients are
expected to achieve during their period
of performance. Programs develop
performance measures customized to a
NOFO-specific public health initiative
to assess actions prescribed by the logic
model with the immediate goal of
monitoring progress and the long-term
goal of improving performance.
Monitoring and reporting of program
performance is required of any nonfederal entity receiving federal funds
under 45 CFR 75.342 which states; ‘‘the
non-Federal entity must monitor its
activities under Federal awards to
assure compliance with applicable
Federal requirements and performance
expectations are being achieved’’. Under
this requested approval, CDC programs
customize a sample ‘‘Performance
Measure Technical Specification
Instrument’’ and a sample ‘‘Performance
Measure Reporting Instrument’’ to
measure, at the local level, the desired
public health outcomes of a particular
public health initiative, in compliance
with the Paperwork Reduction Act

(1) Given the recent increase in grants
and other funding mechanisms used at
CDC to enhance programmatic
flexibility, PMP eligibility will expand
to include all available funding
mechanisms for eligible programs.
(2) PPEO is providing increasing
technical assistance to international
programs. Eligibility will expand to
include both domestic and international
programs.
(3) Many CDC programs are operating
under the 21st Century Cures Act PHE
PRA COVID–19 Emergency Waiver.
This PHE PRA Waiver is likely to be
terminated in 2022. PMP will prioritize
transitioning CDC program performance
measure data collection from the PHE
PRA Waiver to PMP.
(4) Some CDC programs are
developing common performance
metrics across multiple public health
initiatives. PMP will prioritize crossNOFO collaboration with these
programs to increase efficiency.
(5) As programs transition back to
normal function after the COVID–19
pandemic, there has been increased
interest in PMP. The revision will
increase the number of programs that
may participate from 25 Programs to 40,
resulting in an increase of estimated
annual burden hours from 35,000 to
56,000.
CDC requests OMB approval for an
estimated 56,000 annual burden hours.
Participation of respondents is
voluntary. There are no costs to
respondents other than their time.

(PRA). Individual collection requests
submitted under this Generic approval
will include the tailored forms and a
supplementary template. CDC programs
developing new, non-research NOFOs
are eligible to participate.
Currently three CDC programs have
received OMB approval to collect
performance measure data using the
0920–1282 Generic Information
Collection. Two additional programs are
in final CDC clearance for submitting
their Generic ICR (GenIC) requests and
three programs are actively developing
applications. As CDC programs begin to
normalize operations following the
COVID–19 pandemic, numerous other
CDC programs have showed strong
interest in participating in the
Performance Measures Project (PMP)
when: (1) they develop new NOFOs or;
(2) transition current performance
measure data collection from the HHS
Public Health Emergency (PHE) PRA
waiver for Coronavirus Disease 2019
[COVID–19] to the PMP GenIC for
ongoing performance data collection.
This revision is requested to allow
participating CDC programs to continue
performance measure data collection
through the remaining approval period
and for additional programs to use the
GenIC for future performance measure
data collection.
This revision reflects expanded
technical assistance that the Program
Performance and Evaluation Office
(PPEO) provides to CDC programs. CDC
program eligibility to participate in PMP
will be expanded as follows:

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

Average
burden per
response
(in hours)

Total burden
(in hours)

Form name

Recipients of CDC funds for public
health initiatives.

Performance Measures Project Information Collection Tool.

1400

1

40

56,000

Total ...........................................

..........................................................

........................

........................

........................

56,000

Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration

[FR Doc. 2022–15767 Filed 7–22–22; 8:45 am]

[Docket Nos. FDA–2021–N–1112; FDA–
2018–N–4465; FDA–2014–N–1960; FDA–
2018–N–4428; and FDA–2018–N–3353]

BILLING CODE 4163–18–P

lotter on DSK11XQN23PROD with NOTICES1

Number of
responses per
respondent

Type of respondents

Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approvals
AGENCY:

Food and Drug Administration,

HHS.

VerDate Sep<11>2014

17:06 Jul 22, 2022

Jkt 256001

PO 00000

Frm 00042

Fmt 4703

Sfmt 4703

ACTION:

Notice.

The Food and Drug
Administration (FDA) is publishing a
list of information collections that have
been approved by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT:
JonnaLynn Capezzuto, Office of
Operations, Food and Drug
Administration, Three White Flint
North, 10A–12M, 11601 Landsdown St.,
North Bethesda, MD 20852, 301–796–
3794, PRAStaff@fda.hhs.gov.
SUMMARY:

E:\FR\FM\25JYN1.SGM

25JYN1